Jump to Main Content

About ASH

Conflict of Interest Disclosures for Society Leadership

Robert A. Brodsky, MD, Johns Hopkins University 
Consultancy for Alexion Pharmaceuticals and Sobi Pharmaceuticals; Research funding from Alexion Pharmaceuticals; and Honoraria from Sobi Pharmaceuticals and UpToDate.

Mohandas Narla, DSc, New York Blood Center
Consultancy for Forma Therapeutics and New York Blood Center; Honoraria from National Institutes of Health; Membership on a Board or Advisory Committee for Canadian Blood Services; Patents & Royalties from Lawrence Berkeley National Laboratory and UpToDate; Research Funding from National Institutes of Health.

Vice President
Belinda Avalos, MD, Atrium Health Levine Cancer Institute
Membership on a Board or Advisory Committee for Juno CAR-T cell Advisory Board; and Patents & Royalties from BMJ Best Practice.

Cynthia E. Dunbar, MD, National Institutes of Health
Research funding from Be Bio, Disc Medicine, and Novartis; Honoraria from UpToDate.

Joseph R. Mikhael, MD, FRCPC, MEd, Translational Genomics Research Institute
Honoraria from Amgen, GSK, Janssen, Karyopharm, Sanofi, and Takeda; and Consultancy for BMS and Pfizer.

Blood Editor-in-Chief
Nancy Berliner, MD, Brigham and Women's Hospital
Honoraria from UpToDate.

Blood Deputy Editor
Andrew Roberts, MBBS, PhD, Peter MacCallum Cancer Centre
Membership on a Board or Advisory Committee for Victorian Comprehensive Cancer Centre, Australasian Leukaemia and Lymphoma Group, and Cancer Council of Victoria; Research Funding from Abbott, AbbVie, and Genentech; and Patents & Royalties from AbbVie, Genentech, and Walter and Eliza Hall Institute of Medical Research.

Blood Advances Editor-in-Chief
Catherine M. Bollard, MD, Children's National Medical Center
Equity Ownership of Caballeta Bio, Mana Therapeutics, Neximmune, and Repertoire; Membership on a Board or Advisory Committee for Caballeta Bio, Catamaran Bio, Mana Therapeutics, and SOBI; Patents & Royalties from Mana Therapeutics; Consultancy for Neogene and Roche; and Honoraria from Neogene, Roche, and SOBI.

Blood Advances Deputy Editor
Andrew Weyrich, PhD, Oklahoma Medical Research Foundation
Indicated no conflicts of interest.

ASH Clinical News Editor-in-Chief
Aaron T. Gerds, MD, Cleveland Clinic
Membership on a Board or Advisor Committee for AbbVie; Consultancy for CTI BioPharma, Kartos/Telios, Morphosys, Novartis, PharmaEssential, and Sierra Oncology/GSK; and Research funding from CTI BioPharma, Imago Biosciences, and Incyte.

The Hematologist Editor-in-Chief
Shaji Kumar, MD, Mayo Clinic
Consultancy for AbbVie, Amgen, Antagene, AstraZeneca, Beigene, BMS, Genentech, GSK, Oncopeptides, and Sanofi; Research funding from AbbVie, Amgen, AstraZeneca, Bayer, BMS, Carsgen, Celgene, Genentech, Genzyme, GSK, Janssen, Millennium, Novartis, Sanofi, and Takeda; and Membership on a Board or Advisory Committee for Janssen and Takeda.

Executive Director
Martha Liggett, American Society of Hematology
Indicated no conflicts of interest.

Deputy Executive Director
Matthew Gertzog, American Society of Hematology
Equity ownership of Amgen.